The new product portfolio includes swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories. All products will be immediately available through local Ceva companies or its distributors, with no interruption of supply. Products acquired in the acquisition are primarily available in the European Union (EU).
“We are delighted to acquire this range of products and strong pipeline of R&D assets. The knowhow behind these products dates from Pasteur, Rhone-Merieux, Merial and now as Ceva we are conscious that we have a responsibility to maintain this strong veterinary scientific tradition. Our customers can be assured that we will continue to invest to develop the products of both today and tomorrow,” said Dr. Marc Prikazsky, Ceva Chairman and CEO.
Ceva has gained significant market share in swine biology with the addition of 4 Merial vaccines:
Circovac vaccine against Porcine Circovirus type 2
Progressis vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS)
Parvovax vaccine against Porcine Parvovirus
Parvoruvax vaccine against Erysipelas and against Porcine Parvovirus
This acquisition also includes the bovine vaccine Mucosiffa and 4 non-steroidial anti-inflammatories:
Equioxx – equine
Genixine – equine, bovine and swine
Ketofen 1% injection and tablets for dogs and cats
Ketofen 10% injection equine, bovine and swine